Gyre Therapeutics/$GYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gyre Therapeutics
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Ticker
$GYRE
Sector
Primary listing
Employees
579
Headquarters
Website
GYRE Metrics
BasicAdvanced
$685M
514.82
$0.01
-
-
Price and volume
Market cap
$685M
52-week high
$19.00
52-week low
$6.11
Average daily volume
95K
Financial strength
Current ratio
5.395
Quick ratio
4.682
Long term debt to equity
0.596
Total debt to equity
1.076
Profitability
EBITDA (TTM)
11.462
Gross margin (TTM)
95.91%
Net profit margin (TTM)
4.08%
Operating margin (TTM)
9.14%
Effective tax rate (TTM)
24.54%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
4.27%
Return on equity (TTM)
7.84%
Valuation
Price to earnings (TTM)
514.816
Price to revenue (TTM)
6.386
Price to book
7.44
Price to tangible book (TTM)
7.87
Price to free cash flow (TTM)
-404.333
Free cash flow yield (TTM)
-0.25%
Free cash flow per share (TTM)
-0.019
Growth
Revenue change (TTM)
-8.42%
Earnings per share change (TTM)
-101.39%
Bulls say / Bears say
Gyre’s lead candidate Hydronidone achieved statistically significant fibrosis regression versus placebo (52.85% vs. 29.84%, P=0.0002) in a pivotal Phase 3 CHB-associated liver fibrosis trial, with a favorable safety profile supporting an NDA submission in Q3 2025 for potential first-in-class approval (GlobeNewswire) (Nasdaq)
In Q2 2025, revenues increased 6.3% year-on-year to $26.8 million, driven primarily by Etorel’s launch contributing $1.6 million and Contiva’s $1.5 million in sales, demonstrating successful diversification beyond ETUARY (Gyre Therapeutics IR) (TipRanks)
The May 2025 public offering and exercise of underwriters’ option generated gross proceeds of ~$23 million, boosting Gyre’s cash and equivalents to $75.9 million as of June 30, 2025, providing a runway to fund Phase 2 trials and operations for at least 12 months (Gyre Therapeutics IR) (SEC Filing)
ETUARY sales declined by $5.2 million in Q1 2025 compared to Q1 2024, contributing to an 18.7% year-on-year revenue drop and highlighting challenges in sustaining its core franchise amid shifting marketing strategies and competitive pressures (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
GYRE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gyre Therapeutics stock?
Gyre Therapeutics (GYRE) has a market cap of $685M as of October 30, 2025.
What is the P/E ratio for Gyre Therapeutics stock?
The price to earnings (P/E) ratio for Gyre Therapeutics (GYRE) stock is 514.82 as of October 30, 2025.
Does Gyre Therapeutics stock pay dividends?
No, Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders as of October 30, 2025.
When is the next Gyre Therapeutics dividend payment date?
Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Gyre Therapeutics?
Gyre Therapeutics (GYRE) does not currently have a Beta indicator.